Clinical development, not discovery, has become the defining bottleneck in biomedical innovation. Despite rising scientific investment, annual drug approvals have remained stubbornly flat for over a decade. The root cause is structural: fragmented systems, manual workflows, and reactive oversight that no longer scale to the demands of modern trial complexity. This session charts the path from AI ambition to enterprise-scale deployment. We explore why agentic AI represents a fundamental shift in regulated clinical environments, what a structured activation journey looks like in practice, and what today's most capable clinical agents can already do. Watch now!